GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Linperlisib overview

Linperlisib (Intarel) is an antineoplastic agent. It is formulated as a tablet for the oral route of administration. Intarel is indicated for the treatment of adult patients with relapsed and refractory follicular lymphoma who have received at least two systemic treatments in the past.

YY-20394 is under development for the treatment of recurrent or refractory peripheral t-cell lymphoma, relapsed and refractory diffuse large B-cell lymphoma, unspecified T-cell lymphomas, ALK-positive and negative resistance large cell lymphoma, mantle cell lymphoma, B-cell non-Hodgkin lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and other PTCL subtypes, follicular lymphoma, solid tumors and B-cell hematological malignancies, and relapsed/refractory large granular t lymphocytic leukemia. The drug candidate is administered orally. It acts by targeting PI3 kinase delta.

The drug candidate was under development for the treatment of relapsed/refractory thymic cancer, relapsed / refractory autoimmune hemolytic anemia and  chronic lymphocytic leukemia or small lymphocytic lymphoma,  peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, nasopharyngeal Cancer, head and neck cancer, non-small cell lung cancer (NSCLC), small cell lung cancer, gallbladder cancer, cholangiocarcinoma, pancreatic cancer, urothelial carcinoma, renal cell carcinoma cancer, ovarian cancer, endometrial cancer.

Shanghai Yingli Pharmaceutical overview

Shanghai Yingli Pharmaceutical (Yingli Pharma) is a clinical-stage biotechnology company that develops oral small-molecule drugs for oncology and metabolic diseases. The company markets its product, Linperslib tablets for the treatment of follicular lymphoma; and is investigating Linperslib drug candidate to treat peripheral t-cell lymphoma. Its pipeline includes YL-13027 for treatment of advanced solid tumors; YL-15293 to treat lung cancer, colorectal cancer, and pancreatic cancer; and YL-17231 for treatment of KRAS mutant tumors. Yingli Pharma is also developing drugs for non-oncology areas including high uric acid and HIPK2 fibrosis treatments. The company operates in China and the US. Yingli Pharma is headquartered in Shanghai, China.

For a complete picture of Linperlisib’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.